Compare Moderna, Inc. (MRNA) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Noble Corporation plc — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Noble Corporation plc trades at $42.53 (market cap $6.48B). The key difference: Moderna, Inc. is far larger — about 3.6× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.93% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NE | |
|---|---|---|
Market Cap | $23.60B | $6.48B |
Sector | Health | Technology |
52-Week High | $81.80 | $54.37 |
52-Week Low | $22.36 | $25.70 |
Enterprise Value | $19.70B | $7.73B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Noble Corporation (NE) trades at $40.60, down 2.17% on the day, with a neutral technical signal. The company reported mixed Q1 2026 earnings, beating expectations, but missed in the prior two quarters. Recent news highlights new offshore drilling contracts, including a $136.2 million Brunei deal, and the upcoming Q2 2026 earnings report on July 27, 2026. Positive cash flow and a dividend payment of $0.50 per share in June 2026 support shareholder returns.
The outlook is cautiously optimistic, supported by new contracts and a consensus price target of $49.75, implying potential upside. Risks include execution on earnings expectations and offshore drilling market volatility. Analyst sentiment is mixed, with 31% Buy ratings, but the stock's current price is near the low end of the target range, suggesting a balanced risk-reward profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
